International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 51

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–85) and Recommended (1–45) International Nonproprietary Names can be found in *Cumulative List No. 10, 2002* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 51

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–85) et recommandées (1–45) dans la *Liste récapitulative No. 10, 2002* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 51

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–85) y Recomendadas (1–45) se encuentran reunidas en *Cumulative List No. 10, 2002* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada*

adargileukinum alfa

adargileukin alfa — [88-arginine]interleukin 2 (human clone pTIL2-21a) (partly glycosylated)

adargileukine alfa — [88-arginine]interleukine 2 humaine (clone pTIL2-21a) (en partie glycosylée)

adargileukina alfa — [88-arginina]interleukina 2 humana (clon pTIL2-21a) (parcialmente glicosilada)

$C_{695}H_{1124}N_{180}O_{202}S_7$ (peptide)

APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNPKLTRML
TFKFYMPKKA TELKHLQCLE EELKPLEEVL NLAQSKNFHL
RPRDLISRIN VIVLELKGSE TTFMCEYADE TATIVEFLNR
WITFCQSIIS TLT

alamifovirum

alamifovir — bis(2,2,2-trifluoroethyl) [(2-{2-amino-6-[(4-methoxyphenyl)sulfanyl]-9*H*-purin-9-yl}ethoxy)methyl]phosphonate

alamifovir — [[2-[2-amino-6-[(4-méthoxyphényl)sulfanyl]-9*H*-purin-9-yl]éthoxy]méthyl]phosphonate de bis(2,2,2-trifluoroéthyle)

alamifovir — [(2-{2-amino-6-[(4-metoxifenil)sulfanil]-9*H*-purin-9-il}etoxi)metil]fosfonato de bis(2,2,2-trifluoroetilo)

$C_{19}H_{20}F_6N_5O_5PS$



aprinocarsenum

aprinocarsen

2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxyadenosine

aprinocarsen

2'-désoxy-*P*-thioadénylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thioguanylyl-(5'→3')-2'-désoxy-*P*-thioadénylyl-(5'→3')-2'-désoxy-*P*-thioguanylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thioguanylyl-(5'→3')-2'-désoxy-*P*-thioguanylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-2'-désoxy-*P*-thioguanylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxyguanosine

aprinocarseno

2'-desoxi-*P*-tioadenilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tioguanilil-(5'→3')-2'-desoxi-*P*-tioadenilil-(5'→3')-2'-desoxi-*P*-tioguanilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tioguanilil-(5'→3')-2'-desoxi-*P*-tioguanilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-2'-desoxi-*P*-tioguanilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxiguanosina

$C_{196}H_{249}N_{68}O_{105}P_{19}S_{19}$

belimumabum

belimumab

immunoglobulin G1, anti-(human cytokine BAFF) (human monoclonal LymphoStat-B heavy chain), disulfide with human monoclonal LymphoStat-B λ-chain, dimer

bélimumab

immunoglobuline G1, anti-(cytokine BAFF humaine) ; dimère du disulfure entre la chaîne lourde et la chaîne λ de l'anticorps monoclonal humain LymphoStat-B

belimumab

immunoglobulina G1, anti-(citoquina BAFF humana) ; dímero del disulfuro entre la cadena pesada y la cadena λ del anticuerpo monoclonal humano LymphoStat-B

cantuzumabum mertansinum

cantuzumab mertansine

immunoglobulin G1, anti-(mucin CanAg) (human-mouse monoclonal C242 heavy chain), disulfide with human-mouse monoclonal C242 light chain, dimer, conjugate at the 6-amino groups of four lysine residues forming an amide bond with (4*RS*)-4-[(3-{[(1*S*)-2-{[(1*S*,2*R*,3*S*,5*S*,6*S*,16*E*,18*E*,20*R*,21*S*)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1^{10,14}.0^{3,5}]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy}-1-methyl-2-oxoethyl]=methylamino}-3-oxopropyl)disulfanyl]pentanoyl groups

cantuzumab mertansine

immunoglobuline G1, anti-(mucin CanAg) ; dimère du disulfure entre la chaîne lourde et la chaîne légère de l'anticorps monoclonal de souris C242 humanisé dont les groupes 6-amino de quatre lysines sont amidifiés par l'acide (4*RS*)-4-[[3-[[(1*S*)-2-[[(1*S*,2*R*,3*S*,5*S*,6*S*,16*E*,18*E*,20*R*,21*S*)-11-chloro-21-hydroxy-12,20-diméthoxy-2,5,9,16-tétraméthyl-8,23-dioxo-4,24-dioxa-9,22-diazatétracyclo[19.3.1.1^{10,14}.0^{3,5}]hexacosa-10,12,14(26),16,18-pentaén-6-yl]oxy}-1-méthyl-2-oxoéthyl]=méthylamino]-3-oxopropyl]disulfanyl]pentanoïque

cantuzumab mertansina

inmunoglobulina G1, anti-(mucina CanAg) ; dímero del disulfuro entre la cadena pesada y la cadena ligera del anticuerpo monoclonal humanizado de ratón C242 en el que los grupos 6-amino de cuatro lisinas están amidificados por ácido (4*RS*)-4-[[3-[[(1*S*)-2-[[(1*S*,2*R*,3*S*,5*S*,6*S*,16*E*,18*E*,20*R*,21*S*)-11-cloro-21-hidroxi-2,5,9,16-tetrametil -12,20-dimetoxi-4,24-dioxa-8,23-dioxo-9,22-diazatetraciclo[19.3.1.1^{10,14}.0^{3,5}]hexacosa-10,12,14(26),16,18-pentaen-6-il]oxi]-1-metil-2-oxoetil]metilamino]-3-oxopropil]disulfanil]pentanoico



cantuzumab = lg$(NH_2)_4$

cimicoxibum

cimicoxib

4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)-1*H*-imidazol-1-yl]benzenesulfonamide

cimicoxib

4-[4-chloro-5-(3-fluoro-4-méthoxyphényl)-1*H*-imidazol-1-yl]benzènesulfonamide

cimicoxib

4-[4-cloro-5-(3-fluoro-4-metoxifenil)-1*H*-imidazol-1-il]bencenosulfonamida

$C_{16}H_{13}ClFN_3O_3S$



dabuzalgronum

dabuzalgron — *N*-{6-chloro-3-[(4,5-dihydro-1*H*-imidazol-2-yl)methoxy]-2-methylphenyl}methanesulfonamide

dabuzalgron — *N*-[6-chloro-3-[(4,5-dihydro-1*H*-imidazol-2-yl)méthoxy]-2-méthylphényl]méthanesulfonamide

dabuzalgrón — *N*-{6-cloro-3-[(4,5-dihidro-1*H*-imidazol-2-il)metoxi]-2-metilfenil}metanosulfonamida

$C_{12}H_{16}ClN_3O_3S$



dacinostatum

dacinostat — (2*E*)-*N*-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1*H*-indol-3-yl)ethyl]amino}methyl)phenyl]propenamide

dacinostat — (2*E*)-*N*-hydroxy-3-[4-[[(2-hydroxyéthyl)[2-(1H-indol-3-yl)éthyl]amino]méthyl]phényl]prop-2-énamide

dacinostat — (2*E*)-*N*-hidroxi-3-[4-({(2-hidroxietil)[2-(1*H*-indol-3-il)etil]amino}metil)fenil]propenamida

$C_{22}H_{25}N_3O_3$



dalbavancinum

dalbavancin

5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-[(10-methylundecanoyl)amino]- ß-D-glucopyranuronosyl]-38-[[3-(dimethylamino)propyl]carbamoyl]-42-O-a-D-mannopyranosyl-15-Nmethyl(ristomycin A aglicone) (main component)

dalbavancine

acide 2-désoxy-1-O-[(3S,15R,18R,34R,35S,38S,48R,50aR)-5,31-dichloro-38-[[3-(diméthylamino)propyl]carbamoyl]-6,11,34,40,44-pentahydroxy-42-(a-D-mannopyranosyloxy)-15-(méthylamino)-2,16,36,50,51,59-hexaoxo-2,3,16,17,18,19,35,36,37,38,48,49,50,50a-tétradécahydro-20,23:30,33-diéthéno-3,18:35,48-bis(iminométhano)-1H,15H-4,8:10,14:25,28:43,47-tétraméthéno-34H-[1,14,6,22]dioxadiazacyclooctacosino[4,5-m][10,2,16]=benzoxadiazacyclotétracosén-56-yl]-2-[(10-méthylundécanoyl)=amino]-ß-D-glucopyranuronique (composant majeur)

dalbavancina

ácido 1-*O*-[(3*S*,15*R*,18*R*,34*R*,35*S*,38*S*,48*R*,50a*R*)-5,31-dicloro-38-[[3-(dimetilamino)propil]carbamoil]-6,11,34,40,44-pentahidroxi-42-(a-D-manopiranosiloxi)-15-(metilamino)-2,16,36,50,51,59-hexaoxo-2,3,16,17,18,19,35,36,37,38,48,49,50,50a-tetradecahidro-20,23:30,33-dieteno-3,18:35,48-bis(iminometano) -1*H*,15*H*-4,8:10,14:25,28:43,47-tetrameteno-34*H*-[1,14,6,22]dioxadiazaciclooctacosino[4,5-*m*][10,2,16]=benzoxadiazaciclotetracosen-56-il]-2-[(10-metilundecanoil)amino]-2-desoxi-ß-D -glucopiranurónico (componente principal)

C_{88}-H_{100}-Cl_2-N_{10}-O_{28}



deligoparinum natricum

deligoparin sodium — sodium salt of depolymerised heparin obtained by a controlled chemical process based on generation of free radicals by means of metal ions and hydrogen peroxide. The heparin starting material is obtained from porcine intestinal mucosa. The process results in oligosaccharide fragments of heparin of varying lengths. The average relative molecular mass is about 3200 Daltons, ranging from 2250 to 3850 Daltons. The degree of sulfation is approximately 2.5 sulfate residues per disaccharide unit.

déligoparine sodique — sel de sodium d'héparine de basse masse moléculaire obtenue par par dépolymérisation à l'aide de radicaux libres (générés par des ions métalliques et du peroxyde d'hydrogène) d'héparine de muqueuse intestinale de porc. La majorité des composants présentent une structure acide 2-*O*-sulfo-α-D-glucopyranosuronique à l'extrémité non réductrice et une structure 2-désoxy-6-*O*-sulfo-2-(sulfoamino)-D-glucopyranose à l'extrémité réductrice de leur chaîne ; la masse moléculaire relative moyenne est voisine de 3200 (2250 à 3850) ; le degré de sulfatation est voisin de 2,5 par unité disaccharide.

deligoparina sódica — sal sódica de una heparina de baja masa molecular que se obtiene de la heparina de la mucosa intestinal porcina por despolimerización por radicales libres, generados por iones metálicos y peróxido de hidrógeno; la mayoría de los componentes tienen una estructura de ácido 2- *O* -sulfo-α-D-glucopiranosurónico en el extremo no-reductor de la cadena y una estructura 2-desoxy-6-*O*-sulfo-2-(sulfoamino)-D-glucopiranosa en el reductor; la masa molecular media oscila entre 2250 y 3850, con un valor característico de unos 3200; el grado de sulfatación es alrededor de 2,5 por unidad de disacárido.

desvenlafaxinum

desvenlafaxine — 4-[(1*RS*)-2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol

dèsvenlafaxine — 4-[(1*RS*)-2-(diméthylamino)-1-(1-hydroxycyclohexyl)éthyl]phénol

desvenlafaxina — 4-[(1*RS*)-2-(dimetilamino)-1-(1-hidroxiciclohexil)etil]fenol

$C_{16}H_{25}NO_2$



and enantiomer
et énantiomère
y enantiómero

diboterminum alfa

dibotermin alfa — human recombinant bone morphogenic protein-2 (hrBMP-2)

dibotermine alfa — protéine-2 humaine recombinante morphogénique de l'os (PMOrh-2)

dibotermina alfa — proteína-2 humana recombinante morfogénica de hueso (PMOrh-2)

$[C_{571}H_{886}N_{160}O_{164}S_9]_2$

QAKHKQRKRL KSSCKRHPLY VDFSDVGWND WIVAPPGYHA
FYCHGECPFP LADHLNSTNH AIVQTLVNSV NSKIPKACCV
PTELSAISML YLDENEKVVL KNYQDMVVEG CGCR

diquafosolum

diquafosol — P^1,P^4-bis(5'-uridyl) tetrahydrogen tetraphosphate

diquafosol — uridine(5')tétraphospho(5')uridine

dicuafosol — tetrahidrógenotetrafosfato de P^1,P^4-bis(5'-uridilo)

$C_{18}H_{26}N_4O_{23}P_4$



disermolidum

disermolide — (3*Z*,5*S*,6*S*,7*S*,8*R*,9*S*,11*Z*,13*S*,14*S*,15*S*,16*Z*,18*S*)-8,14,18-trihydroxy-19-[(2*S*,3*R*,4*S*,5*R*)-4-hydroxy-3,5-dimethyl-6-oxotetrahydro-2*H*-pyran-2-yl]-5,7,9,11,13,15-hexamethylnonadeca-1,3,11,16-tetraen-6-yl carbamate

disermolide — carbamate de (1*S*,2*S*,3*R*,4*S*,6*Z*,8*S*,9*S*,10*S*,11*Z*,13*S*)-3,9,13-trihydroxy-14-[(2*S*,3*R*,4*S*,5*R*)-4-hydroxy-3,5-diméthyl-6-oxotétrahydro-2*H*-pyran-2-yl]-2,4,6,8,10-pentaméthyl-1-[(1*S*,2*Z*)-1-méthylpenta-2,4-diényl]tétradéca-6,11-diényle

disermolida — carbamato de (3*Z*,5*S*,6*S*,7*S*,8*R*,9*S*,11*Z*,13*S*,14*S*,15*S*,16*Z*,18*S*)-8,14,18-trihidroxi-19-[(2*S*,3*R*,4*S*,5*R*)-4-hidroxi-3,5-dimetil-6-oxotetrahidro-2*H*-piran-2-il]-5,7,9,11,13,15-hexametilnonadeca-1,3,11,16-tetraen-6-ilo

$C_{33}H_{55}NO_8$



edifoligidum

edifoligide

duplex of 2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxyguanosine and 2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-thymidine

édifoligide

2'-désoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxyguanosine et *P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thioadénylyl-(5'→3')-2'-désoxy-*P*-thioadénylyl-(5'→3')-2'-désoxy-*P*-thioguanylyl-(5'→3')-2'-désoxy-*P*-thioguanylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-2'-désoxy-*P*-thioguanylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-2'-désoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-désoxy-*P*-thioadénylyl-(5'→3')-2'-désoxyguanosine partiellement complémentaires

edifoligida

2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-deoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxiguanosina y *P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tioadenilil-(5'→3')-2'-desoxi-*P*-tioadenilil-(5'→3')-2'-desoxi-*P*-tioadenilil-(5'→3')-2'-desoxi-*P*-tioguanilil-(5'→3')-2'-desoxi-*P*-tioguanill-(5'→3')-2'-disoxi-*P*-tioguanilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-2'-desoxi-*P*-tioguanilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-2'-desoxi-*P*-tiocitidilil-(5'→3')-*P*-tiotimidilil-(5'→3')-2'-desoxi-*P*-tioadenilil-(5'→3')-2'-desoxiguanosina parcialmente complementario

(3'-5')d(*P*-thio) (C–T–A–G–A–T–T–T–C–C–C–G–C–G)
(5'-3')d(*P*-thio) (T–A–A–A–G–G–G–C–G–C–C–T–A–G)

edotecarinum

edotecarin — 12-ß-D-glucopyranosyl-2,10-dihydroxy-6-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-12,13-dihydro-6*H*-indolo[2,3-*a*]pyrrolo[3,4-*c*]carbazole-5,7-dione

édotécarine — 12-ß-D-glucopyranosyl-2,10-dihydroxy-6-[[2-hydroxy-1-(hydroxyméthyl)éthyl]amino]-12,13-dihydro-6*H*-indolo[2,3-*a*]pyrrolo[3,4-*c*]carbazole-5,7-dione

edotecarina — 12-ß-D-glucopiranosil-2,10-dihidroxi-6-[[2-hidroxi-1-(hidroximetil)etil]amino]-12,13-dihidro-6*H*-indolo[2,3-*a*]pirrolo=[3,4-*c*]carbazol-5,7-diona

$C_{29}H_{28}N_4O_{11}$



edratidum

edratide — glycyl-L-tyrosyl-L-tyrosyl-L-tryptophyl-L-seryl-L-tryptophyl-L-isoleucyl-L-arginyl-L-glutaminyl-L-prolyl-L-prolylglycyl-L-lysylglycyl-L-glutamyl-L-glutamyl-L-tryptophyl-L-isoleucylglycine

édratide — glycyl-L-tyrosyl-L-tyrosyl-L-tryptophyl-L-séryl-L-tryptophyl-L-isoleucyl-L-arginyl-L-glutaminyl-L-prolyl-L-prolyl-glycyl-L-lysyl-glycyl-L-glutamyl-L-glutamyl-L-tryptophyl-L-isoleucyl-glycine

edratida — glicil-L-tirosil-L-tirosil-L-triptofil-L-seril-L-triptofil-L-isoleucil-L-arginil-L-glutaminil-L-prolil-L-prolilglicil-L-lisilglicil-L-glutamil-L-glutamil-L-triptofil-L-isoleucilglicina

$C_{111}H_{149}N_{27}O_{28}$

H-Gly—Tyr—Tyr—Trp—Ser—Trp—Ile—Arg—Gln—Pro—
10
Pro—Gly—Lys—Gly—Glu—Glu—Trp—Ile—Gly-OH
19

elsilimomabum

elsilimomab — immunoglobulin G1, anti-(human interleukin 6) (mouse monoclonal B-E8 heavy chain), disulfide with mouse monoclonal B-E8 κ-chain, dimer

elsilimomab — immunoglobuline G1, anti-(interleukine 6 humaine) ; dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal de souris B-E8

elsilimomab — inmunoglobulina G1, anti-(interleuquina 6 humana) ; dímero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal de ratón B-E8

elvucitabinum

elvucitabine — 4-amino-5-fluoro-1-[(2*S*,5*R*)-5-(hydroxymethyl)-2,5-dihydro-2-furyl]pyrimidin-2(1*H*)-one

elvucitabine — 4-amino-5-fluoro-1-[(2*S*,5*R*)-5-(hydroxyméthyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1*H*)-one

elvucitabina — 4-amino-5-fluoro-1-[(2*S*,5*R*)-5-(hidroximetil)-2,5-dihidro-2-furil]pirimidin-2(1*H*)-ona

$C_9H_{10}FN_3O_3$



epitumomabum cituxetanum

epitumomab cituxetan — Conjugate of 4-{(2*RS*)-2-[bis(carboxymethyl)amino]-3-({2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)propyl}phenyl isothiocyanate forming a thiourea with the 6-amino of a lysine of immunoglobulin G1, anti-(human episialin) (mouse monoclonal HMFG-1 γ1-chain), disulfide with mouse monoclonal HMFG-1 light chain, dimer

épitumomab cituxétan — dérivé de la thiourée produite par réaction de l'isothiocyanate de 4-[(2*RS*)-2-[bis(carboxyméthyl)amino]-3-[[2-[bis(carboxyméthyl)=amino]éthyl](carboxyméthyl)amino]propyl]phényle avec le 6-amino d'une lysine de l'immunoglobuline G1, anti-(human episialin) ; dimère du disulfure entre la chaîne γ1 et la chaîne légère de l'anticorps monoclonal de souris HMFG-1

epitumomab cituxetán — derivado de la tiourea producido por reacción del isotiocianato de 4-[(2*RS*)-2-[bis(carboximetil)amino]-3-[[2-[bis(carboximetil)amino]etil](carboximetil)amino]propil]fenil con el 6-amino de una lisina de la inmunoglobulina G1, anti-(episialina humana) ; dímero del disulfuro entre la cadena γ1 y la cadena ligera del anticuerpo monoclonal de ratón HMFG-1



and epimer at C*
et l'épimère en C*
y el epímero al C*

eptoterminum alfa

eptotermin alfa — human recombinant bone morphogenetic protein 7 (hrBMP-7) or osteogenic protein-1 (OP-1)

eptotermine alfa — protéine-7 humaine recombinante morphogénique de l'os (PMOrh-7) ou protéine-1 osteogénique (PO-1)

eptotermina alfa — proteína-7 humana recombinante morfogénicas de hueso (PMOrh-7) o proteína-1 osteogénica (PO-1)

$[C_{683}H_{1061}N_{197}O_{208}S_{10}]_2$



exatecanum alideximerum

exatecan alideximer — exatecan linked via the tetrapeptide (glycylglycyl-L-phenylalanylglycyl) to poly[oxy(2-hydroxymethylethylene)oxy=(hydroxymethylmethylene)] partly *O*-substituted with carboxymethyl groups with some carboxy groups amide linked to the tetrapeptide.

exatécan alideximer — exatécan lié par une chaîne tétrapeptidique (glycylglycyl-L-phénylalanylglycyl) à des éthers carboxyméthyliques de poly[oxy(2-hydroxyéthylidène)oxy[1-(hydroxyméthyl)éthylène]]

exatecán alidexímero — exatecán ligado por una cadena tetrapeptídica (glicilglicil-L-fenilalanilglicil) a éteres carboximetílicos de poli[oxi-(2-hidroxietilideno)oxi[1-(hidroximetil)etileno]]



exenatidum

exenatide

L-histidylglycyl-L-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-methionyl-L-glutamyl-L-glutamyl-L-glutamyl-L-alanyl-L-valyl-L-arginyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-glutamyl-L-tryptophyl-L-leucyl-L-lysyl-L-asparaginylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide

exénatide

exendine 4 (*Heloderma suspectum*), synthétique

exenatida

L-histidilglicil-L-glutamilglicil-L-treonil-L-fenilalanil-L-treonil-L-seril-L-aspartil-L-leucil-L-seril-L-lisil-L-glutaminil-L-metionil-L-glutamil-L-glutamil-L-glutamil-L-alanil-L-valil-L-arginil-L-leucil-L-fenilalanil-L-isoleucil-L-glutamil-L-triptofil-L-leucil-L-lisil-L-asparaginilglicilglicil-L-prolil-L-seril-L-serilglicil-L-alanil-L-prolil-L-prolil-L-prolil-L-serinamida

$C_{184}H_{282}N_{50}O_{60}S$



firocoxibum

firocoxib

3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)=phenyl]furan-2(5*H*)-one

firocoxib

3-(cyclopropylméthoxy)-5,5-diméthyl-4-[4-(méthylsulfonyl)=phényl]furan-2(5*H*)-one

firocoxib

3-(ciclopropilmetoxi)-5,5-dimetil-4-[4-(metilsulfonil)fenil]furan-2(5*H*)-ona

$C_{17}H_{20}O_5S$



fispemifenum

fispemifene

2-(2-{4-[(1*Z*)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy}=ethoxy)ethanol

fispémifène

2-[2-[4-[(1*Z*)-4-chloro-1,2-diphénylbut-1-ényl]phénoxy]=éthoxy]éthanol

fispemifeno

2-(2-{4-[(1*Z*)-4-cloro-1,2-difenilbut-1-enil]fenoxi}etoxi)etanol

$C_{26}H_{27}ClO_3$



fluoresceinum lisicolum

fluorescein lisicol — N^6-({3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3*H*),9'-xanthen]-5-yl}thiocarbamoyl)-N^2-(3α,7α,12α-trihydroxy-5β-cholan-24-oyl)-L-lysine

fluorescéine lisicol — acide (2*S*)-6-[[(3',6'-dihydroxy-3-oxospiro[isobenzofurane-1(3*H*),9'-[9*H*]xanthén]-5-yl)thiocarbamoyl]amino]-2-[(3α,7α,12α-trihydroxy-5β-cholan-24-oyl)amino]pentanoïque

fluoresceina lisicol — ácido 5-[({(5*S*)-5-carboxi-5-[(3α,7α,12α-trihidroxi-5β-colan-24-oil)amino]pentil}tiocarbamoil)amino]-2-(6-hidroxi-3-oxo-3*H*-xanten-9-il)benzoico

$C_{51}H_{63}N_3O_{11}S$



freselestatum

freselestat — 2-[5-amino-6-oxo-2-phenylpyrimidin-1(6*H*)-yl]-*N*-[(1*RS*)-1-(5-*tert*-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl]acetamide

frésélestat — 2-(5-amino-6-oxo-2-phénylpyrimidin-1(6*H*)-yl)-*N*-[(1*RS*)-1-[[5-(1,1-diméthyléthyl)-1,3,4-oxadiazol-2-yl]carbonyl]-2-méthylpropyl]=acétamide

freselestat — 2-[5-amino-6-oxo-2-fenilpirimidin-1(6*H*)-il]-*N*-[(1*RS*)-1-(5-*terc*-butil-1,3,4-oxadiazol-2-il)-3-metil-1-oxobutan-2-il]acetamida

$C_{23}H_{28}N_6O_4$



galiximabum

galiximab — immunoglobulin G1, anti-(human CD80 (antigen)) (human-*Macaca irus* monoclonal IDEC-114 heavy chain), disulfide with human-*Macaca irus* monoclonal IDEC-114 λ chain, dimer

galiximab — immunoglobuline G1, anti-(antigène CD80 humain), dimère du disulfure entre la chaîne λ et la chaîne lourde de l'anticorps monoclonal chimérique homme-macaque (*Macaca irus*) IDEC-114

galiximab — inmunoglobulina G1, anti-(antígeno CD80 humano), dímero del disulfuro entre la cadena λ y la cadena pesada del anticuerpo monoclonal quimérico hombre-macaco (*Macaca irus*) IDEC-114

hemoglobinum raffimerum

hemoglobin raffimer — The polyaldehyde [(2*R*,4*S*,6*R*,8*R*,11*S*,13*R*)-1,14-dihydroxy-4-hydroxymethyl-3,5,7,10,12-pentaoxatetradecane-2,4,6,8,11,13-hexacarbaldehyde] derived from raffinose [β-D-fructofuranosyl α-D-galactopyranosyl-(1→6)-α-D-glucopyranoside] by treatment with sodium periodate is reacted with human hemoglobin A_0 at the 2,3-DPG binding pocket. Both intermolecular and intramolecular crosslinking occurs. This product is reduced to generate covalent amine bonds with >95% crosslinked hemoglobin of which about 55% is polymerised.

hémoglobine raffimer — hémoglobine stabilisée et partiellement polymérisée, obtenue par réduction du produit de la réaction du (2*R*,4*S*,6*R*,8*R*,11*S*,13*R*)-1,14-dihydroxy-4-(hydroxyméthyl)-3,5,7,10,12-pentaoxatétradécane-2,4,6,8,11,13-hexacarbaldéhyde (obtenu par oxydation periodique du rafinose) avec l'hémoglobine humaine

hemoglobina rafímero — hemoglobina estabilizada y parcialmente polimerizada, obtenida por reducción del producto de la reacción del (2*R*,4*S*,6*R*,8*R*,11*S*,13*R*)-1,14-dihidroxi-4-(hidroximetil)-3,5,7,10,12-pentaoxatetradecano-2,4,6,8,11,13-hexacarbaldehído (obtenido por oxidación periodica de la rafinosa) con la hemoglobina humana



icofungipenum

icofungipen (1*R*,2*S*)-2-amino-4-methylenecyclopentane-1-carboxylic acid

icofungipen (-)-acide (1*R*,2*S*)-2-amino-4-méthylènecyclopentanecarboxylique

icofungipeno (-)-ácido (1*R*,2*S*)-2-amino-4-metilenociclopentanocarboxílico

$C_7H_{11}NO_2$



icrocaptidum

icrocaptide glycyl-N^2-ethyl-L-lysyl-L-prolyl-L-arginine

icrocaptide glycyl-(N^2-éthyl-L-lysyl)-L-prolyl-L-arginine

icrocaptida glicil-(N^2-etil-L-lisil)-L-prolil-L-arginina

$C_{21}H_{40}N_8O_5$



iferanserinum

iferanserin (*E*)-2'-{2-[(2*S*)-1-methyl-2-piperidyl]ethyl}cinnamanilide

iféransérine (-)-(2*E*)-*N*-[2-[2-[(2*S*)-1-méthylpipéridin-2-yl]éthyl]phényl]-3-phénylprop-2-énamide

iferanserina (-)-(2*E*)-*N*-(2-{2-[(2*S*)-1-metilpiperidin-2-il]etil}fenil)-3-fenilprop-2-enamida

$C_{23}H_{28}N_2O$



istradefyllinum

istradefylline — 8-[(*E*)-2-(3,4-dimethoxyphenyl)vinyl]-1,3-diethyl-7-methyl-3,7-dihydro-1*H*-purin-2,6-dione

istradéfylline — 8-[(*E*)-2-(3,4-diméthoxyphényl)éthényl]-1,3-diéthyl-7-méthyl-3,7-dihydro-1*H*-purin-2,6-dione

istradefilina — 8-[(*E*)-2-(3,4-dimetoxifenil)vinil]-1,3-dietil-7-metil-3,7-dihidro-1*H*-purin-2,6-diona

$C_{20}H_{24}N_4O_4$



ixabepilonum

ixabepilone — (1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1*E*)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione

ixabépilone — (1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihydroxy-8,8,10,12,16-pentaméthyl-3-[(1*E*)-1-méthyl-2-(2-méthylthiazol-4-yl)éthényl]-17-oxa-4-azabicyclo[14.1.0]heptadécane-5,9-dione

ixabepilona — (1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihidroxi-8,8,10,12,16-pentametil-3-[(1*E*)-1-(2-metil-1,3-tiazol-4-il)prop-1-en-2-il]-17-oxa-4-azabiciclo[14.1.0]heptadecano-5,9-diona

$C_{27}H_{42}N_2O_5S$



ladostigilum

ladostigil — (3*R*)-3-(prop-2-ynylamino)indan-5-yl ethyl(methyl)carbamate

ladostigil — éthylméthylcarbamate de (3*R*)-3-(prop-2-ynylamino)-2,3-dihydro-1*H*-indén-5-yle

ladostigilo — etilmetilcarbamato de (3*R*)-3-(prop-2-inilamino)indan-5-ilo

$C_{16}H_{20}N_2O_2$



lapatinibum

lapatinib — *N*-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methylsulfonyl)=ethyl]amino}methyl)-2-furyl]quinazolin-4-amine

lapatinib — *N*-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]quinazolin-4-amine

lapatinib — N-[3-cloro-4-(3-fluorobenciloxi)fenil]-6-[5-({[2-(metilsulfonil)=etil]amino}metil)-2-furil]quinazolin-4-amina

$C_{29}H_{26}ClFN_4O_4S$



lomeguatribum

lomeguatrib — 6-(4-bromothenyloxy)-7*H*-purin-2-amine

lomeguatrib — 6-[(4-bromothiophen-2-yl)methoxy]-7*H*-purin-2-amine

lomeguatrib — 6-(4-bromoteniloxi)-7*H*-purin-2-amina

$C_{10}H_8BrN_5OS$



odiparcilum

odiparcil — 4-methyl-7-(5-thio-β-D-xylopyranosyloxy)-2*H*-chromen-2-one

odiparcil — 4-méthyl-7-[(5-thio-β-D-xylopyranosyl)oxy]-2*H*-1-benzopyran-2-one

odiparcilo — 4-metil-7-(5-tio-β-D-xilopiranosiloxi)-2*H*-cromen-2-ona

$C_{15}H_{16}O_6S$



omigananum

omiganan — L-isoleucyl-L-leucyl-L-arginyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-arginyl-L-arginyl-L-lysinamide

omiganan — L-isoleucyl-L-leucyl-L-arginyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-arginyl-L-arginyl-L-lysinamide

omiganán — L-isoleucil-L-leucil-L-arginil-L-triptofil-L-prolil-L-triptofil-L-triptofil-L-prolil-L-triptofil-L-arginil-L-arginil-L-lisinamida

$C_{90}H_{127}N_{27}O_{12}$



pactimibum

pactimibe — [7-(2,2-dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid

pactimibe — acide [7-[(2,2-diméthylpropanoyl)amino]-4,6-diméthyl-1-octyl-2,3-dihydro-1*H*-indol-5-yl]acétique

pactimiba — ácido [7-(2,2-dimetilpropanamido)-4,6-dimetil-1-octilindolin-5-il] acético

$C_{25}H_{40}N_2O_3$



patupilonum

patupilone — (1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1*E*)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

patupilone — (1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihydroxy-8,8,10,12,16-pentaméthyl-3-[(1*E*)-1-méthyl-2-(2-méthylthiazol-4-yl)éthényl]-4,17-dioxabicyclo[14.1.0]heptadécane-5,9-dione

patupilona — (1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihidroxi-8,8,10,12,16-pentametil-3-[(1*E*)-1-(2-metil-1,3-tiazol-4-il)prop-1-en-2-il]-4,17-dioxabiciclo[14.1.0]heptadecano-5,9-diona

$C_{27}H_{41}NO_6S$



pertuzumabum

pertuzumab — immunoglobulin G1, anti-(human ν (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 κ-chain, dimer

pertuzumab — immunoglobuline G1, anti-(récepteur ν humain), dimère du disulfure entre la chaîne κ et la chaîne lourde de l'anticorps monoclonal de souris humanisé 2C4

pertuzumab — inmunoglobulina G1, anti-(receptor ν humano), dímero del disulfuro entre la cadena κ y la cadena pesada del anticuerpo monoclonal humanizado de ratón 2C4

pixantronum

pixantrone — 6,9-bis[(2-aminoethyl)amino]benzo[*g*]isoquinoline-5,10-dione

pixantrone — 6,9-bis[(2-aminoéthyl)amino]benzo[*g*]isoquinoléine-5,10-dione

pixantrona — 6,9-bis[(2-aminoetil)amino]benzo[*g*]isoquinolina-5,10-diona

$C_{17}H_{19}N_5O_2$



pritumumabum

pritumumab — immunoglobulin G, anti-(human vimentin) (human monoclonal CLN G11 γ1-chain), disulfide with human monoclonal CLN G11 κ-chain, dimer

pritumumab — immunoglobuline G, anti-(vimentine humaine) ; dimère du disulfure entre la chaîne γ1 et la chaîne κ de l'anticorps monoclonal humain CLN H11

pritumumab — inmunoglobulina G, anti-(vimentina humana); dímero del disulfuro entre la cadena γ1 y la cadena κ del anticuerpo monoclonal humano CLN H11

$C_{6440}H_{9968}N_{1708}O_{2016}S_{42}$

ralfinamidum

ralfinamide — (2*S*)-2-[4-(2-fluorobenzyloxy)benzylamino]propanamide

ralfinamide — (+)-(2*S*)-2-[[4-[(2-fluorobenzyl)oxy]benzyl]amino]propanamide

ralfinamida — (+)-(2*S*)-2-[4-(2-fluorobenciloxi)bencilamino]propanamide

$C_{17}H_{19}FN_2O_2$



rebimastatum

rebimastat — *N*-[(2*S*)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]-L-leucyl-N^1,3-dimethyl-L-valinamide

rébimastat — (2*S*)-*N*-[(1*S*)-2,2-diméthyl-1-(méthylcarbamoyl)propyl]-4-méthyl-2-[[(2*S*)-2-sulfanyl-4-(3,4,4-triméthyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide

rebimastat — *N*-[(2*S*)-2-sulfanil-4-(3,4,4-trimetil-2,5-dioxoimidazolidin-1-il)butanoil]-L-leucil-N^1,3-dimetil-L-valinamida

$C_{23}H_{41}N_5O_5S$



segesteronum

segesterone — 17-hydroxy-16-methylene-19-norpregn-4-ene-3,20-dione

ségestérone — 17-hydroxy-16-méthylène-19-norprégn-4-ène-3,20-dione

segesterona — 17-hidroxi-16-metileno-19-norpregn-4-eno-3,20-diona

$C_{21}H_{28}O_3$



semapimodum

semapimod — *N*,*N*′-bis{3,5-bis[1-(carbamimidoylhydrazono)ethyl]phenyl}=decanediamide

sémapimod — *N*,*N*′-bis[3,5-bis[*N*-(carbamimidoylamino)acétimidoyl]phényl]=décanediamide

semapimod — *N*,*N*′-bis{3,5-bis[1-(carbamimidoilhidrazono)etil]fenil}=decanodiamida

$C_{34}H_{52}N_{18}O_2$



sufugolixum

sufugolix	5-{[benzyl(methyl)amino]methyl}-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-*d*]pyrimidine-2,4(1*H*,3*H*)-dione
sufugolix	1-[4-[5-[(benzylméthylamino)méthyl]-1-(2,6-difluorobenzyl)-2,4-dioxo-3-phényl-1,2,3,4-tétrahydrothiéno[2,3-*d*]pyrimidin-6-yl]phényl]-3-méthoxyurée
sufugolix	5-{[bencil(metil)amino]metil}-1-(2,6-difluorobencil)-6-[4-(3-metoxiureido)fenil]-3-feniltieno[2,3-*d*]pirimidina-2,4(1*H*,3*H*)-diona

$C_{36}H_{31}F_2N_5O_4S$



tacapenemum

tacapenem	(+)-(4*R*,5*S*,6*S*)-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[(3*R*)-5-oxopyrrolidin-3-yl]sulfanyl]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
tacapénem	(+)-acide (4*R*,5*S*,6*S*)-6-[(1*R*)-1-hydroxyéthyl]-4-méthyl-7-oxo-3-[[(3*R*)-5-oxopyrrolidin-3-yl]sulfanyl]-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylique
tacapenem	(+)-ácido (4*R*,5*S*,6*S*)-6-[(1*R*)-1-hidroxietil]-4-metil-7-oxo-3-[[(3*R*)-5-oxopirrolidin-3-il]sulfanil]-1-azabiciclo[3.2.0]hept-2-eno-2-carboxílico

$C_{14}H_{18}N_2O_5S$



tafluprostum

tafluprost	isopropyl (5*Z*)-7-{(1*R*,2*R*,3*R*,5*S*)-2-[(1*E*)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl}hept-5-enoate
tafluprost	(5*Z*)-7-[(1*R*,2*R*,3*R*,5*S*)-2-[(1*E*)-3,3-difluoro-4-phénoxybut-1-ényl]-3,5-dihydroxycyclopentyl]hept-5-énoate de 1-méthyléthyle
tafluprost	(5*Z*)-7-{(1*R*,2*R*,3*R*,5*S*)-2-[(1*E*)-3,3-difluoro-4-fenoxibut-1-enil]-3,5-dihidroxiciclopentil}hept-5-enoato de isopropilo

$C_{25}H_{34}F_2O_5$



talizumabum

talizumab	immunoglobulin G, anti-(human immunoglobulin E Fc region) (human-mouse monoclonal Hu901 γ-chain), disulfide with human-mouse monoclonal Hu901 κ-chain, dimer
talizumab	immunoglobuline G, anti-(région Fc de l'immunoglobuline E humaine), dimère du disulfure entre la chaîne κ et la chaîne γ de l'anticorps monoclonal de souris humanisé Hu901
talizumab	inmunoglobulina G, anti-(región Fc de la inmunoglobulina E humana), dímero del disulfuro entre la cadena κ y la cadena γ del anticuerpo monoclonal humanizado de ratón Hu901

technetium (99mTc) nitridocadum

technetium (99mTc) nitridocade	(*SPY*-5-21)-bis[ethoxy(ethyl)dithiocarbamato-κ*S*,κ*S'*]nitrido=[^{99m}Tc]technetium
technétium (99mTc) nitridocade	(*SPY*-5-21)-bis(éthoxyéthyldithiocarbamato-κ*S*,κ*S'*)nitrido=[^{99m}Tc]technétium
tecnecio (99mTc) nitridocado	(*SPY*-5-21)-bis(etoxietilditiocarbamato-κ*S*,κ*S'*)nitrido[^{99m}Tc]tecnecio

$C_{10}H_{20}N_3O_2S_4{}^{99m}Tc$



tesofensinum

tesofensine (1*R*,2*R*,3*S*,5*S*)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane

tésofensine (1*R*,2*R*,3*S*,5*S*)-3-(3,4-dichlorophényl)-2-(éthoxyméthyl)-8-méthyl-8-azabicyclo[3.2.1]octane

tesofensina (1*R*,2*R*,3*S*,5*S*)-3-(3,4-diclorofenil)-2-(etoximetil)-8-metil-8-azabiciclo[3.2.1]octano

$C_{17}H_{23}Cl_2NO$



tifenazoxidum

tifenazoxide 6-chloro-*N*-(1-methylcyclopropyl)-1,1-dioxo-1,4-dihydro-1λ^6-thieno[3,2-*e*][1,2,4]thiadiazin-3-amine

tifénazoxide 1,1-dioxyde de 6-chloro-*N*-(1-méthylcyclopropyl)-4*H*-thiéno[3,2-*e*]-1,2,4-thiadiazin-3-amine

tifenazóxido 1,1-dióxido de 6-cloro-*N*-(1-metilciclopropil)-4*H*-tieno[3,2-*e*]-1,2,4-tiadiazin-3-amina

$C_9H_{10}ClN_3O_2S_2$



tisocalcitatum

tisocalcitate isopropyl (1*S*,3*R*,5*Z*,7*E*,22*E*,24*R*)-1,3,24-trihydroxy-9,10-secocholesta-5,7,10(19),22-tetraene-25-carboxylate

tisocalcitate (5*Z*,7*E*,22*E*,24*R*)-1α,3β,24-trihydroxy-9,10-sécocholesta-5,7,10(19),22-tétraène-25-carboxylate de 1-méthyléthyle

tisocalcitato (1*S*,3*R*,5*Z*,7*E*,22*E*,24*R*)-1,3,24-trihidroxi-9,10-secocolesta-5,7,10(19),22-tetraeno-25-carboxilato de isopropilo

$C_{31}H_{48}O_5$



ulifloxacinum

ulifloxacin	(1*RS*)-6-fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-4*H*-[1,3]thiazeto[3,2-*a*]quinoline-3-carboxylic acid
ulifloxacin	acide (1*RS*)-6-fluoro-1-méthyl-4-oxo-7-(pipérazin-1-yl)-4*H*-[1,3]thiazéto[3,2-*a*]quinoléine-3-carboxylique
ulifloxacino	ácido (1*RS*)-6-fluoro-1-metil-4-oxo-7-(piperazin-1-il)-4*H*-[1,3]tiazeto[3,2-*a*]quinolina-3-carboxílico

$C_{16}H_{16}FN_3O_3S$



and enantiomer
et énantiomère
y enantiómero

vareniclinum

varenicline	7,8,9,10-tetrahydro-6*H*-6,10-methanoazepino[4,5-*g*]quinoxaline
varénicline	(6*R*,10*S*)-7,8,9,10-tétrahydro-6,10-méthano-6*H*-pyrazino[2,3-*h*][3]benzazépine
vareniclina	7,8,9,10-tetrahidro-6*H*-6,10-metanoazepino[4,5-*g*]quinoxalina

$C_{13}H_{13}N_3$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 04
Dénominations communes internationales recommandées (DCI Rec.): Liste 04
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 04
(Crónica de la OMS, Vol. 16, N° 4, Abril de 1962)

p. 158	*suprimase* metodilazina	*insértese* metdilazina

Recommended International Nonproprietary Names (Rec. INN): List 06
Dénominations communes internationales recommandées (DCI Rec.): Liste 06
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 06
(WHO Chronicle, Vol. 20, No. 11, 1967)
(Chronique OMS, Vol. 20, N° 11, 1967)
(Crónica de la OMS, Vol. 21, N° 11, 1967)

	lauromacrogolum 400	
p. 427	lauromacrogol 400	*replace the description by the following:* polyethylene glycol monododecyl ether, the name is followed by a number (400) corresponding approximately to the average molecular mass of the polyethylene glycol portion
p. 474	lauromacrogol 400	*remplacer la description par la suivante:* α-dodécyl-ω-hydroxypoly(oxyéthylène), la masse moyenne de la partie macrogol (≈ 44*n*+18) est indiquée entre parenthèses après la dénomination
p. 340	lauromacrogol 400	*sustitúyase la descripción por la siguiente:* éter monododecílico del polietilen glicol, al nombre le sigue un número (400) que corresponde aproximadamente a la masa molecular media de la fracción polietilenglicol

Recommended International Nonproprietary Names (Rec. INN): List 40
Dénominations communes internationales recommandées (DCI Rec.): Liste 40
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 40
(WHO Drug Information, Vol. 12, No. 3, 1998)

p. 194	*supprimer* pregabaline	*insérer* prégabaline

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impairs des listes des DCIs proposées.

El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en los números impares de las listas de DCI propuestas.